Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Pharmacodynamic evaluation and safety assessment of treatment with antibodies to serum amyloid P component in patients with cardiac amyloidosis: an open-label Phase 2 study and an adjunctive immuno-PET imaging study

Autor: Wechalekar, A, Antoni, G, Al Azzam, W, Bergström, M, Biswas, S, Chen, C, Cheriyan, J, Cleveland, M, Cookson, L, Galette, P, Janiczek, RL, Kwong, RY, Lukas, MA, Millns, H, Richards, D, Schneider, I, Solomon, SD, Sörensen, J, Storey, J, Thompson, D, van Dongen, G, Vugts, DJ, Wall, A, Wikström, G, Falk, RH

Publikováno v: Wechalekar, A, Antoni, G, Al Azzam, W, Bergström, M, Biswas, S, Chen, C, Cheriyan, J, Cleveland, M, Cookson, L, Galette, P, Janiczek, R L, Kwong, R Y, Lukas, M A, Millns, H, Richards, D, Schneider, I, Solomon, S D, Sörensen, J, Storey, J, Thompson, D, van Dongen, G, Vugts, D J, Wall, A, Wikström, G & Falk, R H 2022, ' Pharmacodynamic evaluation and safety assessment of treatment with antibodies to serum amyloid P component in patients with cardiac amyloidosis : an open-label Phase 2 study and an adjunctive immuno-PET imaging study ', BMC Cardiovascular Disorders, vol. 22, no. 1, 49 . https://doi.org/10.1186/s12872-021-02407-6
BMC Cardiovascular Disorders, 22(1). BioMed Central
BMC Cardiovascular Disorders, 22(1):49. BioMed Central

Background In a Phase I study treatment with the serum amyloid P component (SAP) depleter miridesap followed by monoclonal antibody to SAP (dezamizumab) showed removal of amyloid from liver, spleen and kidney in patients with systemic amyloidosis. We

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52d43a27d4681e51d8685ea3c4e47388
https://doi.org/10.1186/s12872-021-02407-6

DE KOEBOES IN DE Onderafdeeling Koeboestreken DER Residentie Palembang

Autor: VAN DONGEN, G. J., WESLY, L. F.

Publikováno v: Bijdragen tot de Taal-, Land- en Volkenkunde van Nederlandsch-Indië, 1910 Jan 01. 63(3/4), 177-336.

Externí odkaz: https://www.jstor.org/stable/20769590

Correction to:[89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer (European Journal of Nuclear Medicine and Molecular Imaging, (2020), 47, 4, (849-859), 10.1007/s00259-019-04555-6)

Autor: van Helden, E. J., Elias, S. G., Gerritse, S. L., van Es, S. C., Boon, E., Huisman, M. C., van Grieken, N. C.T., Dekker, H., van Dongen, G. A.M.S., Vugts, D. J., Boellaard, R., van Herpen, C. M.L., de Vries, E. G.E., Oyen, W. J.G., Brouwers, A. H., Verheul, H. M.W., Hoekstra, O. S., der Houven van Oordt, C. W.Menke van

Publikováno v: van Helden, E J, Elias, S G, Gerritse, S L, van Es, S C, Boon, E, Huisman, M C, van Grieken, N C T, Dekker, H, van Dongen, G A M S, Vugts, D J, Boellaard, R, van Herpen, C M L, de Vries, E G E, Oyen, W J G, Brouwers, A H, Verheul, H M W, Hoekstra, O S & der Houven van Oordt, C W M V 2020, ' Correction to : [89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer (European Journal of Nuclear Medicine and Molecular Imaging, (2020), 47, 4, (849-859), 10.1007/s00259-019-04555-6) ', European Journal of Nuclear Medicine and Molecular Imaging, vol. 47, no. 10, pp. 2481 . https://doi.org/10.1007/s00259-020-04908-6

The Electronic Supplementary Materials are missing in the original article. Kindly check the Electronic Supplementary Materials in this article. The Publisher regrets this error.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_____10172::0c0938e5110305b00cc0d60e8bed533c
https://research.vumc.nl/en/publications/0c4bd5ae-9627-44b4-9087-a375c3e76a80